Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEO-24 vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline, a xanthine derivative, acts as a non-selective phosphodiesterase (PDE) inhibitor (primarily PDE3 and PDE4), increasing intracellular c AMP and c GMP in airway smooth muscle and inflammatory cells. It also antagonizes adenosine receptors (A1, A2), stimulates endogenous catecholamine release, and may enhance histone deacetylase activity, reducing inflammation.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of symptoms of chronic asthma (FDA-approved),Treatment of chronic obstructive pulmonary disease (COPD) (FDA-approved),Off-label: Apnea of prematurity (though caffeine is preferred),Off-label: Post-extubation stridor in neonates
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
300-600 mg orally once daily, extended-release capsule; individualize based on serum theophylline concentration targeting 5-15 mcg/m L.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is approximately 3–8 hours in adults (non-smokers), 4–5 hours in smokers (due to enzyme induction), and highly variable in neonates (24–36 hours) and children (1–9 hours). Half-life is prolonged in cirrhosis (up to 30 hours), heart failure, and with concomitant medications (e.g., cimetidine, erythromycin).
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via cytochrome P450 CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolized to 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid. Saturable metabolism leads to non-linear pharmacokinetics at high doses.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Approximately 90% of theophylline is eliminated hepatically via metabolism (principally CYP1A2 and CYP3A4), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug is minimal (about 5%) in adults. Biliary/fecal excretion accounts for less than 1%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 53–65% bound to albumin in plasma. Binding is saturable and decreases at high concentrations, leading to increased free fraction.
55–65% bound to plasma proteins, primarily albumin.
Volume of distribution (Vd) is approximately 0.3–0.7 L/kg (average 0.45 L/kg), indicating distribution into total body water. Vd is larger in neonates and smaller in obese individuals. It does not correlate with therapeutic effect; therapeutic range is based on serum concentration.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral bioavailability is nearly 100% for theophylline base (rapid absorption). For THEO-24 sustained-release capsules, bioavailability is 100% relative to immediate-release, though absorption is slower and p H-dependent. Food may slightly decrease rate but not extent of absorption.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No specific GFR-based dose adjustment recommended; monitor serum theophylline levels and adjust dose accordingly due to potential accumulation in renal impairment.
No dose adjustment required for renal impairment.
For Child-Pugh class A: reduce dose by 50%; Child-Pugh class B: reduce dose by 50% and monitor levels; Child-Pugh class C: avoid use or use extreme caution with 25% of normal dose and frequent monitoring.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Initial dose: 10-14 mg/kg/day orally in divided doses every 12 hours (extended-release); maximum 300 mg/day for children <1 year; adjust based on serum theophylline levels.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at lower end of dosing range (300 mg once daily) with cautious titration; monitor serum theophylline levels closely due to decreased clearance and increased risk of toxicity.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
Narrow therapeutic index; serum concentrations should be monitored (therapeutic range 10-20 mcg/m L for asthma/COPD).,Toxicity risk increased with doses > 400 mg/day or serum levels > 20 mcg/m L; symptoms include nausea, vomiting, diarrhea, headache, insomnia, irritability, and at higher levels, tachycardia, seizures, and cardiac arrest.,Risk of status epilepticus and fatal outcome with seizures.,Use caution in patients with peptic ulcer disease, hyperthyroidism, seizure disorders, hepatic or renal impairment, or cardiac disease (e.g., arrhythmias, congestive heart failure).,Interactions with drugs that inhibit CYP1A2 (e.g., cimetidine, ciprofloxacin, fluvoxamine, macrolides) increase toxicity.,Interactions with drugs that induce CYP1A2 (e.g., rifampin, phenobarbital, carbamazepine, smoking) decrease efficacy.,Elderly, acutely ill, or patients with cor pulmonale have reduced clearance.,Hypersensitivity to theophylline or other xanthines.,Pregnancy category C (risks not ruled out).
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component of the formulation.,Seizure disorders (relative contraindication; may lower seizure threshold).,Active peptic ulcer disease (relative).,Uncontrolled cardiac arrhythmias (relative).
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
High-protein, low-carbohydrate diets may decrease theophylline clearance. Consumption of charcoal-grilled meats may increase elimination rate. Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may add to stimulant effects and increase toxicity risk.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Theophylline (THEO-24) is pregnancy category C. First trimester: Limited data suggest no increased risk of major malformations; however, rare associations with cardiac defects reported. Second and third trimesters: Possible fetal tachycardia, irritability, and jitteriness at birth due to placental transfer; no known teratogenicity.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk; M/P ratio approximately 0.7. Infant serum levels can reach therapeutic or toxic ranges. Potential for irritability and insomnia in breastfed infants. Use with caution; monitor infant for signs of theophylline toxicity.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
In pregnancy, theophylline clearance may decrease in the third trimester due to reduced hepatic metabolism. Dose adjustments may be required; monitor serum levels every 2-4 weeks. Postpartum, clearance returns to prepregnancy levels, necessitating dose reduction if dose was increased.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Monitor serum theophylline concentrations; target 5-15 mcg/m L for efficacy and safety. Titrate dose based on steady-state levels. Avoid in seizure disorders unless on anticonvulsants. Cigarette smoking and charbroiled meats increase clearance, requiring dose adjustments. Reduce dose in hepatic impairment, heart failure, and with drugs that inhibit CYP1A2 (e.g., ciprofloxacin, fluvoxamine).
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not double doses if missed.,Avoid caffeine-containing products (coffee, tea, chocolate, cola) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew the extended-release capsules; swallow whole.,Inform all healthcare providers you are taking this medication.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEO-24 vs AEROLATE SR, answered by our medical review team.
THEO-24 is a Bronchodilator that works by Theophylline, a xanthine derivative, acts as a non-selective phosphodiesterase (PDE) inhibitor (primarily PDE3 and PDE4), increasing intracellular c AMP and c GMP in airway smooth muscle and inflammatory cells. It also antagonizes adenosine receptors (A1, A2), stimulates endogenous catecholamine release, and may enhance histone deacetylase activity, reducing inflammation.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEO-24 and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEO-24 is: 300-600 mg orally once daily, extended-release capsule; individualize based on serum theophylline concentration targeting 5-15 mcg/m L.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEO-24 and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEO-24 is classified as Category C. Theophylline (THEO-24) is pregnancy category C. First trimester: Limited data suggest no increased risk of major malformations; however, rare associations with cardiac defects repo. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.